MiMedx Group

MDXG92

High Quality

$9.06arrow_drop_down1.83%-$0.16

High Quality

MDXG92

$9.06

arrow_drop_down1.83%-$0.16

High Quality

Performance History

Key Stats
Open	$9.18
Prev. Close	$9.24
EPS	0.57
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	8.55	9.24
52 Week Range	5.57	9.50

Ratios







EPS	0.57

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About MiMedx Group (MDXG)

MiMedx Group, Inc. is a medical technology company that specializes in the development and manufacturing of advanced wound care and regenerative biologics. The company's primary product line includes amniotic tissue-based allografts, which are used in the treatment of chronic wounds such as diabetic foot ulcers and venous leg ulcers. These allografts are derived from the placental tissues and are processed to retain their natural healing properties. MiMedx also offers other innovative products for wound care, including collagen-based dressings and advanced wound care trays.

MiMedx Group, Inc. (MDXG) stock has a long history of steady growth. Over the past five years, the stock has consistently increased in value, reflecting the company's strong financial performance and market position. The stock price has experienced some volatility over this period, but overall, it has shown a positive trend. As of the most recent trading day, the stock was trading at $12.50 per share, with a market capitalization of $1.48 billion.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Joseph H. Capper
Headquarters: Marietta
Employees: 867
Exchange: NASDAQ

Keep an eye on MiMedx Group

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of MiMedx Group (MDXG)?

MiMedx Group (MDXG) has a market capitalization of $1.33B. The average daily trading volume is 8.92, indicating the stock's liquidity and investor engagement.

help

What is MiMedx Group's (MDXG) price per share?

The current price per share for MiMedx Group (MDXG) is $9.06. The stock has seen a price change of -$0.17 recently, indicating a -1.84% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for MiMedx Group (MDXG)?

For MiMedx Group (MDXG), the 52-week high is $9.5, which is 4.86% from the current price. The 52-week low is $5.57, the current price is 62.66% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is MiMedx Group (MDXG) a growth stock?

MiMedx Group (MDXG) has shown an average price growth of -7.34% over the past three years. It has received a score of 83 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying MiMedx Group as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is MiMedx Group (MDXG) stock price performance year to date (YTD)?

As of the latest data, MiMedx Group (MDXG) has a year-to-date price change of 15.12%. Over the past month, the stock has experienced a price change of 58.95%. Over the last three months, the change has been 40.25%. Over the past six months, the figure is 13.25%.

help

Is MiMedx Group (MDXG) a profitable company?

MiMedx Group (MDXG) has a net income of $67.44M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 83.01% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 13.63% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $321.48M, with a revenue growth rate of 20.03%, providing insight into the company's sales performance and growth. The gross profit is $266.84M. Operating income is noted at $37.12M. Furthermore, the EBITDA is $75.66M.